The usefulness of serum beta-2 microglobulin as a biomarker for evaluating renal function decline in type II diabetes mellitus
Keywords:beta-2 microglobulin, diabetic nephropathy, diabetes mellitus, macroalbuminuria
Background and objective: Serum beta-2 microglobulin (β2M) has been used as a useful clinical marker of chronic kidney dysfunction. The current study aims to evaluate the diagnostic accuracy of β2M for the early detection of diabetic nephropathy among Iraqi patients with type II diabetes mellitus.
Methods: The study included 84 participants divided into four groups, three of them were type II diabetics and the fourth is the healthy individuals’ (control) group. The diabetic’ subgroups were named according to the Micral test as: normoalbuminuria (21 patients), microalbuminuria (21 patients), and macroalbuminuria group (21 patients). The control group included 21, age- and sex-matched, healthy participants. Biochemical markers for diabetes mellitus as well as β2M were determined for each participant and then were analyzed statistically.
Results: The serum β2M of normoalbuminuria group was (2.86±0.95 µg/mL), microalbuminuria group was (5.06±1.97 µg/mL) and macroalbuminuria group (3.6±1.59 µg/mL). The results showed significant increase (p˂0.05) in the β2M level of microalbuminuria group when compared with that of normoalbuminuria and macroalbuminuria groups. In addition, a highly significant increase (p˂0.01) in β2M concentration was observed in microalbuminuria group when compared with that of the control group.
Conclusions: β2M can be used as a useful biomarker for the early detection of diabetic nephropathy.
Abdollahzadeh Estakhri et al. “An investigation of the relationship between beta-2 microglobulin (β2M) and inflammatory factors (serum levels of CRP and albumin) and high density lipoproteins (HDL) in hemodialysis patients”. Mod Med Lab J 1(1) (2017), pp. 17–22. DOI: 10.30699/mmlj17-01-04.
C L Cheung, K S Lam, and B M Cheung. “Serum β-2 microglobulin predicts mortality in people with diabetes”. Eur J Endocrinol 169(1) (2013), pp. 1–7. DOI: 10.1530/EJE-13-0003.
C P Argyropoulos, S S Chen, Y - H Ng, et al. “Rediscovering beta-2 microglobulin as a biomarker across the spectrum of kidney diseases”. Front Med (Lausanne) 4 (2017), pp. 73–73. DOI: 10.3389/fmed.2017.00073.
D Puthiyottil et al. “Role of Urinary Beta 2 Microglobulin and Kidney Injury Molecule-1 in Predicting Kidney Function at One Year Following Acute Kidney Injury”. Int J Nephrol Renovasc Dis 14 (2021), pp. 225–234. DOI: 10.2147/IJNRD.S319933.
D Puthiyottil et al. “Role of urinary beta 2 microglobulin and kidney injury molecule-1 in predicting kidney function at one year following acute kidney injury”. Int J Nephrol Renovasc Dis 14 (2021), pp. 225–234. DOI: 10.2147/IJNRD.S319933.
F A Karlsson, L Wibell, and P E Evrin. “beta 2-Microglobulin in clinical medicine”. Scand J Clin Lab Invest Suppl 154 (1980), pp. 27–37.
G Behairy et al. “Role of serum cystatin-C and beta-2 microglobulin as early markers of renal dysfunction in children with beta thalassemia major”. Int J Nephrol Renovasc Dis 10 (2017), pp. 261–268. DOI: 10.2147/IJNRD.S142824.
H Y Lu, X Y Ning, and Y Q Chen. “Predictive Value of Serum Creatinine, Blood Urea Nitrogen, Uric Acid, and β2-Microglobulin in the Evaluation of Acute Kidney Injury after Orthotopic Liver Transplantation”. Chin Med J (Engl) 131(9) (2018), pp. 1059–1066.
J A Light et al. “Serum beta-2-microglobulin: an adjunctive monitoring test in renal transplantation”. Proc Clin Dial Transplant Forum 10 (1980), pp. 67–73.
J D Herrero-Morín, S Málaga, and N Fernández. “Cystatin C and beta2-microglobulin: markers of glomerular filtration in critically ill children”. Crit Care 11 (2007), pp. 59–59. DOI: 10.1186/cc5923.
J E Jensen et al. “The MICRAL test for diabetic microalbuminuria: predictive values as a function of prevalence”. Scand J Clin Lab Invest 56(2) (1996), pp. 117–122. DOI: 10.3109/00365519609088597.
J W Becker and G N Reeke. “Three-dimensional structure of beta 2-microglobulin”. Proc Natl Acad Sci 82(12) (1985), pp. 4225–4229. DOI: 10.1073/pnas.82.12.4225.
L Li, M Dong, and X - G Wang. “The implication and significance of beta 2 microglobulin: a conservative multifunctional regulator”. Chin Med J (Engl) 129(4) (2016), pp. 448–455. DOI: 10.4103/0366-6999.176084.
M C Foster, L A Inker, and C Y Hsu. “Filtration markers as predictors of ESRD and mortality in Southwestern American Indians with type 2 diabetes”. Am J Kidney Dis 66(1) (2015), pp. 75–83. DOI: 10.1053/j.ajkd.2015.01.013.
M Colombo, H C Looker, and B Farran. “Serum kidney injury molecule 1 and β2-microglobulin perform as well as larger biomarker panels for prediction of rapid decline in renal function in type 2 diabetes”. Diabetologia 62(1) (2019), pp. 156–168. DOI: 10.1007/s00125-018-4741-9.
M K Kim, K J Yun, and H J Chun. “Clinical utility of serum beta-2-microglobulin as a predictor of diabetic complications in patients with type 2 diabetes without renal impairment”. Diabetes Metab 40(6) (2014), pp. 459–465. DOI: 10.1016/j.diabet.2014.08.002.
Sedighi, S Abediankenari, and B Omranifar. “Association between plasma Beta-2 microglobulin level and cardiac performance in patients with chronic kidney disease”. Nephrourol Mon 7(1) (2014). DOI: 10.5812/numonthly.23563.
T B Drüeke and Z A Massy. “Progress in uremic toxin research: beta2-microglobulin”. Seminars in Dialysis 22 (2009), pp. 378–380. DOI: 10.1111/j.1525-139X.2009.00584.x.
V Topçiu-Shufta et al. “Association of beta-2 microglobulin with inflammation and dyslipidemia in high-flux membrane hemodialysis patients”. Med Arch 70(5) (2016), pp. 348–350. DOI: 10.5455/medarh.2016.70.348-350.
Z Stanga et al. “Factors other than the glomerular filtration rate that determine the serum beta-2-microglobulin level”. PLoS One 8(8) (2013), e72073–e72073. DOI: 10.1371/journal.pone.0072073.
Copyright (c) 2022 Zainab A. Hussein, Sura A. Abdulsattar, Issam N. Salman
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The authors retain all proprietary rights, including copyright, such as patent and trade mark rights and rights to any process or procedure described in the article.